Sign inJoin waitlistJoin the waitlist

John Kane

, Professor and Chair of Psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell · Clinical Center at the National Institutes of Health

Credentials: · ·

History

psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Department · Clinical Center at the National Institutes of Health
Present
Clinical Center at the National Institutes of Health
Present

Psychiatry
1972–1976
Institute

Research

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
Archives of General Psychiatry · 1988 · First of 4 authors · 3,620 citations
Remission in schizophrenia: proposed criteria and rationale for consensus
Review · American Journal of Psychiatry · 2005 · 1,844 citations
The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability
Archives of General Psychiatry · 1992 · 1,153 citations

CC
Christoph Correll
225 papers
DR
Delbert Robinson
81 papers
Jeffrey Lieberman
79 papers
AM
Anil Malhotra
69 papers
Michael Birnbaum
30 papers · 12 as a resident
PM
Peter Manu
29 papers
René Kahn
29 papers
BK
Bruce Kinon
27 papers
PS
Philip Szeszko
27 papers
Stephen Marder
24 papers
SW
Scott Woods
23 papers
CC
Cheryl Corcoran
22 papers

Grants

ProCAN: Psychosis Risk Outcomes Compound Assessment Network
National Institute of Mental Health · U01
PI · $48.7M · Yale University
2024–2029
ProNET: Psychosis-Risk Outcomes Network
National Institute of Mental Health · U01
PI · $69.3M · Yale University
2020–2027
Early-Phase Schizophrenia: Practice-Based Research to Improve Treatment Outcomes (ESPRITO)
National Institute of Mental Health · R01
PI · $7.7M · Feinstein Institute for Medical Research
2019–2025
Developing Strategies to Reduce DUP in the Age of Social Medial and the Internet
National Institute of Mental Health · R34
Contact PI · $818.8K · Feinstein Institute for Medical Research
2014–2018

Clinical trials

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
Principal investigator · Completed · Phase 2
LB Pharmaceuticals Inc.
2023–2024
Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics
Principal investigator · Completed · Phase 4
Vanguard Research Group
2014–2019
Improving Care and Reducing Cost Study
Principal investigator · Completed
Northwell Health
2013–2015
An Integrated Program for the Treatment of First Episode of Psychosis
Principal investigator · Completed
Northwell Health
2010–2017